Royalty Pharma downgraded by UBS with a new price target
$RPRX
Biotechnology: Pharmaceutical Preparations
Health Care
UBS downgraded Royalty Pharma from Buy to Neutral and set a new price target of $28.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/30/2026 | $49.00 | Neutral → Buy | UBS |
| 9/30/2025 | $42.00 | Buy | Goldman |
| 5/16/2025 | $51.00 | Overweight | Morgan Stanley |
| 6/3/2024 | $28.00 | Buy → Neutral | UBS |
| 6/14/2022 | $47.00 | Buy | UBS |
| 5/13/2022 | $53.00 | Sector Outperform | Scotiabank |
| 4/27/2022 | $56.00 | Buy | Goldman |
| 4/14/2022 | $50.00 | Neutral → Overweight | JP Morgan |
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired a portion of Neurimmune’s royalty interest in AstraZeneca’s cliramitug for up to $425 million, including $125 million upfront. Cliramitug is a Phase 3 first-in-class TTR-fibril-depleting antibody designed to remove amyloid deposits in patients with TTR amyloidosis with cardiomyopathy (ATTR-CM), a progressive, degenerative and fatal disease caused by misfolded proteins that accumulate in the heart. Currently approved therapies for ATTR-CM slow disease progression by preventing ATTR accumulation but do not target amyloid already accumulated in the heart. Cliramitug is currently
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on September 10, 2026, to shareholders of record at the close of business on August 14, 2026. About Royalty Pharma plcFounded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companie
NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the "Investors" page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days. About Royalty Pharma plc Founded in 1996, Royalty Phar
4 - Royalty Pharma plc (0001802768) (Issuer)
4 - Royalty Pharma plc (0001802768) (Issuer)
4 - Royalty Pharma plc (0001802768) (Issuer)
8-K - Royalty Pharma plc (0001802768) (Filer)
8-K - Royalty Pharma plc (0001802768) (Filer)
144 - Royalty Pharma plc (0001802768) (Subject)
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired a portion of Neurimmune’s royalty interest in AstraZeneca’s cliramitug for up to $425 million, including $125 million upfront. Cliramitug is a Phase 3 first-in-class TTR-fibril-depleting antibody designed to remove amyloid deposits in patients with TTR amyloidosis with cardiomyopathy (ATTR-CM), a progressive, degenerative and fatal disease caused by misfolded proteins that accumulate in the heart. Currently approved therapies for ATTR-CM slow disease progression by preventing ATTR accumulation but do not target amyloid already accumulated in the heart. Cliramitug is currently
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on September 10, 2026, to shareholders of record at the close of business on August 14, 2026. About Royalty Pharma plcFounded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companie
NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the "Investors" page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days. About Royalty Pharma plc Founded in 1996, Royalty Phar
UBS upgraded Royalty Pharma from Neutral to Buy and set a new price target of $49.00
Goldman initiated coverage of Royalty Pharma with a rating of Buy and set a new price target of $42.00
Morgan Stanley initiated coverage of Royalty Pharma with a rating of Overweight and set a new price target of $51.00
NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and implementation of artificial intelligence capabilities across Royalty Pharma. "Lucas's appointment marks a significant step in our commitment to implementing cutting‑edge technology across our platform," said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. "By incorporating intelligent automation, advanced analytics and AI-driven decision support, we are strengthening how we evaluate and invest in royalties and support our partners. Luc
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced an expansion of its leadership team. Greg Butz will join Royalty Pharma as Executive Vice President, Partnering & Investments, effective June 2026. Greg joins Royalty Pharma from Bank of America, where he was the Global Co-Head of Healthcare Investment Banking. "We are thrilled that Greg will join Royalty Pharma and strengthen our leadership team," said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. "Greg brings tremendous experience advising healthcare companies on capital raising, strategy, and mergers and acquisitions and he will be a critical addition t
NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty business in Asia. Ken joins Royalty Pharma from Morgan Stanley, where he was Head of Asia Pacific Healthcare Investment Banking. Asia-based biotechnology companies are now prolific creators of innovative therapeutics. In 2025, the out-licensing of Chinese medicines alone comprised over $130 billion of announced transaction value, up from approximately $14 billion in 2021, as multinational pharmaceutical companies increasingly recognized the va
SC 13G/A - Royalty Pharma plc (0001802768) (Subject)
SC 13D/A - Royalty Pharma plc (0001802768) (Subject)
SC 13G/A - Royalty Pharma plc (0001802768) (Subject)